What is Belviq? How does Belviq work?

Belviq (Lorcaserin) is a weight loss drug and a diet pill approved by the FDA in 2012 and was launched in the U.S. in June 2013. Eisai is the manufacturer of both Belviq and Belviq XR (the extended release). Doctors prescribed Belviq as a weight loss drug for adults who were obese or overweight and couldn’t lose weight with diet and exercise alone.

The drug is to be used with a reduced-calorie diet and increased physical activity. The diet drug lorcaserin helps people lose weight by increasing a person’s feeling of being full so that she eats less.

A normal BMI is considered to be 18.5 to 24.9 kg/m². Doctors prescribed the diet pill to people with the following BMI:

  • 30 kg/m² or greater (considered to be obese)
  • 27 kg/m² or greater (considered to be overweight) when the patient also has other weight-related conditions such as high blood pressure, high cholesterol or type 2 diabetes

Belviq side effects

A clinical study with 12,000 people using the diet pill showed an increased risk of cancer including:

  • Pancreatic cancer
  • Colorectal cancer
  • Lung cancer
  • Other cancers

Belviq Lawsuit

The lawyers of Laminack, Pirtle & Martines are actively reviewing cases of individuals who took Belviq or Belviq XR (lorcaserin) and have been diagnosed with cancer. We’re also taking cases with family members of loved ones who took the weight loss drug and died from cancer. We’re filing lawsuits against the manufacturer of Belviq for failing to properly study and evaluate Belviq and providing misleading information about the safety of the diet pill.

Please call 833-791-7999.

FDA Removes Belviq from US market

On January 14, 2020, the FDA issued a public alert about a clinical trial with Belviq and Belviq XR (lorcaserin). In the 5-year trial, patients showed a possible increase risk of cancer. The FDA said it would continue to evaluate the results and would communicate its final conclusion when it completed its review. On February 13, 2020, the FDA asked Eisai, the manufacturer of Belviq and Belviq XR (lorcaserin), to voluntarily withdraw the diet pill from the U.S. market because the clinical trials showed an increased rick of cancer. When the FDA originally approved lorcaserin in 2012, it required Eisai to conduct a clinical trial to evaluate the risk of cardiovascular problems. Instead of showing cardiovascular problems, the clinical trial showed an increased risk of different type of cancers including pancreatic, colorectal, and lung. The results showed more patients taking lorcaserin or Belviq were diagnosed with cancer than those on the placebo. The increase in rate was one additional cancer diagnosis per 470 patients. The study noted the increase in cancer using Belviq came after the patients had used the diet pill for more than a year.

The FDA said, “We are taking this action because we believe that the risks of lorcaserin outweigh its benefits based on our completed review of results from a randomized clinical trial assessing safety.”

The FDA told doctors to stop prescribing the weight loss drug, contact their patients and tell them to stop taking it. FDA offered instructions for disposing of the drug safely

Experienced Diet Drug Attorneys

Attorneys at Laminack, Pirtle & Martines are experienced in personal injury lawsuits, and they’ve been at the forefront of many large jury verdicts.

In 2004, attorneys Rick Laminack, Tom Pirtle & Buffy Martines were key players in a lawsuit against the manufacturer of the diet drug fen-phen. The case involved a mother who died of lung disease after taking the diet drug Pondimin. The jury awarded the wife’s family more than $1 billion, the largest personal injury award in history (at the time of the award).

In the last 40 years, attorneys for Laminack, Pirtle & Martines have tried and won dozens of other pharmaceutical and medical device cases. LPM trial lawyers won two of the first jury trials awarding damages to women injured by silicone breast implants, resulting in jury verdicts of more than $60,000,000.

What’s the difference between Belviq, Belviq XR and Lorcaserin?

Lorcaserin is the drug’s medical name.  Belviq is the brand name and how it is marketed by its manufacturer, Eisai, Inc.   Belviq XR is an extended-release form of Belviq prescribed as one daily dose as opposed to twice daily.

What should I do if I’m taking Belviq?

The FDA recommends patients stop taking Belviq and talk to their doctors about other weight-loss medicines or programs.  Belviq tablets should be taken to a drug take back location.  If you can’t get to a location, the FDA recommends:

  • Mixing Belviq tablets with an unappealing substance such as dirt or cat litter. Do not crush them.
  • Put the mixture in a sealed bag.
  • Throw the bag in your home trash.
  • Remove all labeling from the bottles and then recycle as appropriate

If you’ve taken Belviq and had side effects, the FDA recommends you report your issues to the FDA MedWatch program.

What’s the process for hiring a Belviq lawyer? And does a Belviq attorney do for me?

If you’ve taken a Belviq and then developed cancer, you could be eligible for financial compensation to help with your medical bills, pain and suffering, loss of wages and earning capabilities and other punitive and compensatory damages.  Our Belviq cancer lawyers are ready to answer your questions. There is no obligation when you call. Your Belviq case will be handled individually by one of our experienced trial attorneys.  You will not be put into a class action lawsuit. The first step in the process is to contact our office through the chat window, 1-833-791-7999, or our contact form on this Belviq website.

We’ll ask you a few questions about taking Belviq and your cancer diagnosis to get started. Our Belviq lawyers will walk you through the process.  There are no upfront costs to hiring a Belviq attorney.  We don’t get paid until we win your case. Our attorneys have proven courtroom experience.  We’ve won major cases against pharmaceutical companies for a previous diet drug. We also won two jury cases for women injured by silicone breast implants.

Why did the FDA ask the Belviq manufacturer to remove the drug from the market?

The FDA asked Eisai, the manufacturer of Belviq and Belviq XR, to voluntarily withdrawal the weight-loss pill because a randomized safety clinical trial showed an increase risk of cancer.   The FDA believes the risk of taking Belviq outweighs the benefit of the weight loss drug.

The safety trial was conducted as a requirement when the FDA approved the drug in 2012.  The trial was to evaluate the risk of cardiovascular problems.  Instead of finding heart problems, the trial showed people who took the weight loss drug Belviq had an increased risk of pancreatic cancer, colorectal cancer and lung cancer

Common side effects of taking Belviq

In addition to the cancer risk, Belviq has other common side effects including:

  • Low blood sugar
  • Headache
  • Dizziness
  • Constipation
  • Toothache
  • Anxiety
  • Cough
  • Blurred Vision
  • Pain in the back or muscles
  • Fatigue
  • Difficulty falling or staying asleep


Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq Belviq XR (lorcaserin) https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr

FDA requests the withdrawal of the weight loss-rug Belviq, Belviq XR (lorcaserin) from the market.   https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market

Belviq.com https://www.belviq.com/

Belviq Side Effects by Likelihood and Severity https://www.webmd.com/drugs/2/drug-164439/belviq-oral/details/list-sideeffects


What makes Laminack, Pirtle & Martines a successful litigation law firm?
One word: Commitment.

We promise a total commitment to fighting for compensation for victims of negligence.

Contact Info

  5020 Montrose Blvd, 9th Floor
Houston, TX 77006-6533


Toll Free: 800-805-2778

Fax: 713-292-2755

 This email address is being protected from spambots. You need JavaScript enabled to view it.